3/5/2
DIALOG(R)File 351:Derwent WPI

007094652
WPI Acc No: 1987-094649/*198714*
XRAM Acc No: C87-039355
Treating chronic graft-host reactions and autoimmune diseases - esp. systemic Lupus erythematosus, by admin. of 5-methyl-isoxazole-4-carboxylic acid anilide or its metabolite
Patent Assignee: HOECHST AG (FARH); BAYER AG (FARB)
Inventor: BARTLETT R R; KAEMMERER F; SCHLEYERBACH R; KAMMERER F J; SCHLEYERBA R
Number of Countries: 019 Number of Patents: 023
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
DE 3534440	A	19870402	DE 3534440	A	19850927	198714	B
EP 217206	A	19870408	EP 86112687	A	19860913	198714	
JP 62072614	A	19870403	JP 86226368	A	19860926	198719	
AU 8663167	A	19870402				198725	
ZA 8607347	A	19870324	ZA 867347	A	19860926	198727	
ES 2001996	A	19880701	ES 862206	A	19860926	198924	
US 4965276	A	19901023	US 86911328	A	19860925	199045	
CA 1275251	C	19901016				199047	
IL 80149	A	19901129				199105	
EP 559238	A1	19930908	EP 86112687	A	19860913	199336	
			EP 93106367	A	19860913		
JP 5208908	A	19930820	JP 86226368	A	19860926	199338	
			JP 92322998	A	19860926		
EP 217206	B1	19931103	EP 86112687	A	19860913	199344	
DE 3689252	G	19931209	DE 3689252	A	19860913	199350	
			EP 86112687	A	19860913		
US 5268382	A	19931207	US 86911328	A	19860925	199350	
			US 90575603	A	19900831		
			US 92870327	A	19920417		
JP 95029918	B2	19950405	JP 86226368	A	19860926	199518	
			JP 92322998	A	19860926		
EP 559238	B1	19950503	EP 86112687	A	19860913	199522	
			EP 93106367	A	19860913		
DE 3650315	G	19950608	DE 3650315	A	19860913	199528	
			EP 93106367	A	19860913		
JP 7165694	A	19950627	JP 86226368	A	19860926	199534	
			JP 94219865	A	19860926		
US 5459163	A	19951017	US 86911328	A	19860925	199547	
			US 90575603	A	19900831		
			US 92870327	A	19920417		
			US 93119840	A	19930913		
JP 2514190	B2	19960710	JP 86226368	A	19860926	199632	
JP 2607848	B2	19970507	JP 86226368	A	19860926	199723	
			JP 94219865	A	19860926		
US 5679709	A	19971021	US 86911328	A	19860925	199748	
			US 90575603	A	19900831		
			US 92870327	A	19920417		
			US 93119840	A	19930913		
			US 95478847	A	19950607		
BR 1100652	A3	19980428	BR 971100652	A	19970507	199823	

Priority Applications (No Type Date): DE 3534440 A 19850927
Cited Patents: 5.Jnl.Ref; A3...8924; EP 13376; EP 257882; No-SR.Pub; DE 2555789; US 4061767; US 4284786
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
DE 3534440	A		11		
EP 217206	A	G			
Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE					
US 4965276	A		10		
EP 559238	A1	G	13	C07C-255/23	Related to application EP 86112687
Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE					
JP 5208908	A		8	A61K-031/275	Div ex application JP 86226368
EP 217206	B1	G	14	A61K-031/42	
Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE					
DE 3689252	G			A61K-031/42	Based on patent EP 217206
US 5268382	A		10	A61K-031/42	Div ex application US 86911328 Cont of application US 90575603 Div ex patent US 4965276
JP 95029918	B2		8	A61K-031/275	Div ex application JP 86226368 Based on patent JP 5208908
EP 559238	B1	G	6	C07C-255/23	Related to application EP 86112687
Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE					
DE 3650315	G			C07C-255/23	Based on patent EP 559238
JP 7165694	A		7	C07C-255/23	Div ex application JP 86226368
US 5459163	A			A61K-031/42	Div ex application US 86911328 Cont of application US 90575603 Div ex application US 92870327 Div ex patent US 4965276 Div ex patent US 5268382
JP 2514190	B2		9	A61K-031/275	Previous Publ. patent JP 62072614
JP 2607848	B2		7	C07C-255/23	Div ex application JP 86226368 Previous Publ. patent JP 7165694
US 5679709	A		10	A61K-031/275	Div ex application US 86911328 Cont of application US 90575603 Div ex application US 92870327 Div ex application US 93119840 Div ex patent US 4965276 Div ex patent US 5268382 Div ex patent US 5459163
BR 1100652	A3			C07C-255/23	

Abstract (Basic): DE 3534440 A

The use of amides of formulae (I) and (II), or the salts of (II), to make pharmaceuticals for treating chronic graft-host diseases and autoimmune diseases is new. Pref. oral formulations contain 10-200, esp. 50-100, mg (I) or (II); intra-venous formulations contain 1-30, esp. 5-10, mg, and rectal formulations contain 50-300, esp. 100-200 mg.

USE/ADVANTAGE - (I) is already known (EP 13376) as an anti-inflammatory. It, and its metabolite (II) (Ann. Rept. Med. Chem., 18 (1983) 171), are now found to be immunomodulators, so are useful for preventing transplant rejection and particularly for treating systemic lupus erythematosus. Unlike known immuno-suppressants, they do not induce a general suppression of the immune system, so allow recovery of reduced T-cell function. For adults, the pref. daily dose is 50 - 200 mg orally; 10 - 30 mg intravenously and 100 - 300 mg rectally.

(Dwg.0/5)

Title Terms: TREAT; CHRONIC; GRAFT; HOST; REACT; AUTO; IMMUNE; DISEASE; SYSTEMIC; LUPUS; ERYTHEMATOSUS; ADMINISTER; METHYL; ISOXAZOLE; CARBOXYLIC ; ACID; ANILIDE; METABOLITE
Derwent Class: B03; B05
International Patent Class (Main): A61K-031/275; A61K-031/42; C07C-255/23
International Patent Class (Additional): A61K-031/16; A61K-031/36; A61K-031/425; C07C-121/41; C07C-255/24; C07D-261/18
File Segment: CPI